Bupropion and Metabolite, Serum or Plasma
Use to optimize drug therapy and monitor patient adherence.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Timing of specimen collection: Predose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (K2 or K3EDTA), pink (K2EDTA), green (Heparin) or gray (Potassium oxalate or Sodium Fluoride).
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 14 days
|Therapeutic Range||10-100 ng/mL||850-1500 ng/mL|
|Toxic Level||Greater than or equal to 400 ng/mL||Greater than or equal to 2000 ng/mL|
Bupropion is an antidepressant drug indicated for the treatment of major depressive disorder. The drug is also used as treatment for smoking cessation. The therapeutic range is based on serum predose (trough) draw at steady-state concentration. Bupropion is primarily metabolized to hydroxybupropion, which has about 50 percent of the activity of the parent drug. The pharmacokinetics of bupropion and metabolite are influenced by drug-drug interactions that affect CYP2B6 metabolism. Patients with renal or hepatic impairment may require a dose reduction. Adverse effects may include seizures, hypertension, nausea, vomiting, neuropsychiatric and cardiac abnormalities.
Laboratory Developed Test (LDT)
80338 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
- Wellbutrin (Bupropion)
- Zyban (Bupropion)